Literature DB >> 6307784

Two new serotypes of enteric adenovirus causing infantile diarrhoea.

I Uhnoo, G Wadell, L Svensson, M Johansson.   

Abstract

Fastidious enteric adenovirus have recently been recognized as an important cause of acute gastroenteritis in young children. Their inability to grow in vitro has hampered classification by conventional methods. With modern immunological and chemical techniques the enteric adenoviruses have been shown to be distinct from the 39 established human adenovirus serotypes. In a prospective study of the viral, bacterial and parasitic aetiology of acute gastroenteritis 410 children and 205 age-matched controls were studied. An enteropathogenic agent was detected in 67% of the diarrhoeic patients and 57% were of viral origin. Rotavirus was the major agent found in 43% of the patients whereas adenovirus was found in 13%. Of the 50 adenovirus specimens, so far fully characterized by electron microscopy, ELISA-assays, DNA-restriction analysis and isolation studies 70% were identified as enteric adenoviruses. Two serotypes, adeno 40 and 41, were detected representing the new subgroups F and G. Twelve of 17 paired serum specimens, from children with enteric adenovirus showed a significant rise in hemagglutination inhibition titers. Infection with enteric adenoviruses showed 2 small seasonal peaks in summer and late winter. Infection occurred early in life, 85% of the children aged less than 3 years. Diarrhoea was the main symptom with an average duration of 9 days. Adenovirus type 41 seemed to cause diarrhoea of longer duration. Fever and vomiting was mild with a mean of 2 days. Respiratory symptoms occurred in 20% of the cases. The incubation period could be estimated as 7 days. Virus was excreted for 10-14 days.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307784

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  29 in total

1.  Sensitivity of subgroup F adenoviruses to interferon.

Authors:  C T Tiemessen; A H Kidd
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

2.  Examination of uncommon clinical isolates of human adenoviruses by restriction endonuclease analysis.

Authors:  G W Hammond; G Mauthe; J Joshua; C K Hannan
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

3.  Selection of nonfastidious adenovirus species in 293 cells inoculated with stool specimens containing adenovirus 40.

Authors:  M Brown
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

4.  DNA restriction analysis of adenovirus prototypes 1 to 41.

Authors:  T Adrian; G Wadell; J C Hierholzer; R Wigand
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

5.  Adenovirus 41 growth in semi-permissive cells shows multiple-hit kinetics.

Authors:  C T Tiemessen; A H Kidd
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Interaction of Human Enterochromaffin Cells with Human Enteric Adenovirus 41 Leads to Serotonin Release and Subsequent Activation of Enteric Glia Cells.

Authors:  Sonja Westerberg; Marie Hagbom; Anandi Rajan; Vesa Loitto; B David Persson; Annika Allard; Johan Nordgren; Sumit Sharma; Karl-Eric Magnusson; Niklas Arnberg; Lennart Svensson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

7.  Fast identification of adenovirus 40/41 in infants with enteritis.

Authors:  R Wigand
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

8.  Enteric adenoviruses in childhood diarrhea.

Authors:  P Raj; N Bhandari; M K Bhan
Journal:  Indian J Pediatr       Date:  1988 Nov-Dec       Impact factor: 1.967

9.  Helper function of adenovirus 2 for adenovirus 41 antigen synthesis in semi-permissive and non-permissive cells.

Authors:  C T Tiemessen; A H Kidd
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

10.  Antibody response to enteric adenovirus types 40 and 41 in sera from people in various age groups.

Authors:  T Shinozaki; K Araki; H Ushijima; R Fujii
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.